PRLD · Prelude Therapeutics Inc
AI read · Good for PRLD
The AI's read
Prelude said the FDA cleared its IND to start a Phase 1 study of PRT13722. This moves the drug into human testing and creates a path to clinical data.
Prelude received FDA clearance to begin a Phase 1 study of PRT13722 for HR+ breast cancer. That advances its clinical program and may create future data catalysts.
Prelude said the FDA cleared its IND to start a Phase 1 study of PRT13722. This moves the drug into human testing and creates a path to clinical data.
Follow Prelude Therapeutics Inc (PRLD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PRLD